Futura Medical plc has announced positive results from a Home User Test for its Eroxon® product and a new prototype, Eroxon® 'Intense', showing statistically significant greater sensorial effect in the first two minutes for the Intense formula. In the study of 223 subjects with mild to moderate erectile dysfunction, both formulations demonstrated high efficacy, with subjects reporting satisfaction with erection hardness in 70-71% of encounters and sufficient duration for intercourse in 84-85% of encounters. The study also confirmed that partner application increased effectiveness and significantly higher erection maintenance. Favorable 4- or 5-star ratings were received by 49% for Eroxon® and 53% for Intense, with over 50% likely to purchase either product. Data for regulatory filings for Eroxon® Intense in Europe and the USA has been generated, with a "Special" 510K submission filed with the US FDA, and regulatory authorization expected in H1 2026.
